CD19 and lymphopenia: CLD reportedly has a peripheral mechanism of action that includes an immunomodulatory effect with an anti-inflammatory shift in the T cell cytokine environment and lymphopenia in the CD4+, CD8+, and CD19+ (up to 90% of the CD19+ population) cell subpopulations [9,12].